TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SN1R337
| Market Closed - Deutsche Boerse AG 20:51:12 26/06/2024 BST | ||
| 1.78 EUR | 0.00% |
|
| Current month | +11.25% | ||
| 1 month | +9.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 1.78 | 0.00% |
| 25/06/24 | 1.78 | -0.56% |
| 24/06/24 | 1.79 | +2.29% |
| 21/06/24 | 1.75 | 0.00% |
| 20/06/24 | 1.75 | +3.55% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 08:51 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SN1R33 |
| ISIN | DE000SN1R337 |
| Date issued | 13/06/2022 |
| Strike | 285.2 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.89 € |
|---|---|
| Lowest since issue | 0.09 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474
USD
Average target price
465.5
USD
Spread / Average Target
-1.79%
- Stock Market
- Certificates
- Certificat
